股関節変形性関節症鎮痛剤の世界市場2020-2026:経口、注射、外用

QYResearchが発行した調査報告書(QYR20AP01015)
◆英語タイトル:Global Hip Osteoarthritis Pain Drug Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP01015
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:136
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、股関節変形性関節症鎮痛剤の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、股関節変形性関節症鎮痛剤のグローバル市場動向、メーカー別競争状況、種類別市場規模(経口、注射、外用)、用途別市場規模(医療、パーソナルケア)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・股関節変形性関節症鎮痛剤の種類別市場2015-2026:経口、注射、外用
・股関節変形性関節症鎮痛剤の用途別市場2015-2026:医療、パーソナルケア
・股関節変形性関節症鎮痛剤の北米市場分析
・股関節変形性関節症鎮痛剤のアジア市場分析
・股関節変形性関節症鎮痛剤の中南米市場分析
・股関節変形性関節症鎮痛剤の中東・アフリカ市場分析
・関連企業情報:Pfizer、Johnson and Johnson、GlaxoSmithKline、Bayer、Eli Lilly、Novartis、Sanofi、Horizon Pharma、Abbott、Mylan、Daiichi Sankyo、TEVA、Almatica Pharma、Astellas Pharma、Tide Pharmaceutical、Iroko Pharmaceuticals、Hengrui Pharmaceutical、Abiogen Pharma
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

Hip Osteoarthritis Pain Drug is to relieve pain, and cannot slow the progress of osteoarthritis.In 2019, the global Hip Osteoarthritis Pain Drug market size was US$ xx million and is forecast to US$ xx million in 2026, growing at a CAGR of 5.5% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Hip Osteoarthritis Pain Drug.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Hip Osteoarthritis Pain Drug market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Hip Osteoarthritis Pain Drug market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Hip Osteoarthritis Pain Drug market. Readers of the report can become informed about current and future trends of the global Hip Osteoarthritis Pain Drug market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Hip Osteoarthritis Pain Drug markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Hip Osteoarthritis Pain Drug market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Hip Osteoarthritis Pain Drug market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Hip Osteoarthritis Pain Drug market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Hip Osteoarthritis Pain Drug market is segmented into
Oral
Injection
External

Market Segment by Application, the Hip Osteoarthritis Pain Drug market is segmented into
Medical Care
Personal Care

This report includes the following manufacturers; we can also add the other companies as you want.
Pfizer
Johnson and Johnson
GlaxoSmithKline
Bayer
Eli Lilly
Novartis
Sanofi
Horizon Pharma
Abbott
Mylan
Daiichi Sankyo
TEVA
Almatica Pharma
Astellas Pharma
Tide Pharmaceutical
Iroko Pharmaceuticals
Hengrui Pharmaceutical
Abiogen Pharma

The study objectives are:
To analyze and research the global Hip Osteoarthritis Pain Drug status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Hip Osteoarthritis Pain Drug manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Hip Osteoarthritis Pain Drug are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Hip Osteoarthritis Pain Drug Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Hip Osteoarthritis Pain Drug Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Oral
1.3.3 Injection
1.3.4 External
1.4 Market Segment by Application
1.4.1 Global Hip Osteoarthritis Pain Drug Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Medical Care
1.4.3 Personal Care
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Hip Osteoarthritis Pain Drug Revenue (2015-2026)
2.1.1 Global Hip Osteoarthritis Pain Drug Revenue (2015-2026)
2.1.2 Global Hip Osteoarthritis Pain Drug Sales (2015-2026)
2.2 Hip Osteoarthritis Pain Drug Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Hip Osteoarthritis Pain Drug Sales by Regions (2015-2020)
2.2.2 Global Hip Osteoarthritis Pain Drug Revenue by Regions (2015-2020)
2.3 Global Top Hip Osteoarthritis Pain Drug Regions (Countries) Ranking by Market Size
2.4 Hip Osteoarthritis Pain Drug Industry Trends
2.4.1 Hip Osteoarthritis Pain Drug Market Top Trends
2.4.2 Market Drivers
2.4.3 Hip Osteoarthritis Pain Drug Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Hip Osteoarthritis Pain Drug Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Hip Osteoarthritis Pain Drug Manufacturers by Sales (2015-2020)
3.1.1 Global Hip Osteoarthritis Pain Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Hip Osteoarthritis Pain Drug Sales in 2019
3.2 Global Top Manufacturers Hip Osteoarthritis Pain Drug by Revenue
3.2.1 Global Hip Osteoarthritis Pain Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Hip Osteoarthritis Pain Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hip Osteoarthritis Pain Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hip Osteoarthritis Pain Drug as of 2019)
3.4 Global Hip Osteoarthritis Pain Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Hip Osteoarthritis Pain Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Hip Osteoarthritis Pain Drug Market
3.7 Key Manufacturers Hip Osteoarthritis Pain Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Hip Osteoarthritis Pain Drug Historic Market Review by Type (2015-2020)
4.1.2 Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2015-2020)
4.1.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2015-2020)
4.1.4 Hip Osteoarthritis Pain Drug Price by Type (2015-2020)
4.1 Global Hip Osteoarthritis Pain Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Hip Osteoarthritis Pain Drug Sales Forecast by Type (2021-2026)
4.2.3 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Type (2021-2026)
4.2.4 Hip Osteoarthritis Pain Drug Price Forecast by Type (2021-2026)

5 Global Hip Osteoarthritis Pain Drug Market Size by Application
5.1 Global Hip Osteoarthritis Pain Drug Historic Market Review by Application (2015-2020)
5.1.2 Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2015-2020)
5.1.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2015-2020)
5.1.4 Hip Osteoarthritis Pain Drug Price by Application (2015-2020)
5.2 Global Hip Osteoarthritis Pain Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Hip Osteoarthritis Pain Drug Sales Forecast by Application (2021-2026)
5.2.3 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Application (2021-2026)
5.2.4 Hip Osteoarthritis Pain Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Hip Osteoarthritis Pain Drug Breakdown Data by Company
6.2 North America Hip Osteoarthritis Pain Drug Breakdown Data by Type
6.3 North America Hip Osteoarthritis Pain Drug Breakdown Data by Application
6.4 North America Hip Osteoarthritis Pain Drug Breakdown Data by Countries
6.4.1 North America Hip Osteoarthritis Pain Drug Sales by Countries
6.4.2 North America Hip Osteoarthritis Pain Drug Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Company
7.2 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Type
7.3 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Application
7.4 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Countries
7.4.1 Europe Hip Osteoarthritis Pain Drug Sales by Countries
7.4.2 Europe Hip Osteoarthritis Pain Drug Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Company
8.2 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Type
8.3 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Application
8.4 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Regions
8.4.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales by Regions
8.4.2 Asia Pacific Hip Osteoarthritis Pain Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Hip Osteoarthritis Pain Drug Breakdown Data by Company
9.2 Latin America Hip Osteoarthritis Pain Drug Breakdown Data by Type
9.3 Latin America Hip Osteoarthritis Pain Drug Breakdown Data by Application
9.4 Latin America Hip Osteoarthritis Pain Drug Breakdown Data by Countries
9.4.1 Latin America Hip Osteoarthritis Pain Drug Sales by Countries
9.4.2 Latin America Hip Osteoarthritis Pain Drug Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Type
10.2 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Application
10.3 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Countries
10.3.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Countries
10.3.2 Middle East and Africa Hip Osteoarthritis Pain Drug Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Pfizer Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Pfizer Hip Osteoarthritis Pain Drug Products and Services
11.1.5 Pfizer SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 Johnson and Johnson
11.2.1 Johnson and Johnson Corporation Information
11.2.2 Johnson and Johnson Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Johnson and Johnson Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Johnson and Johnson Hip Osteoarthritis Pain Drug Products and Services
11.2.5 Johnson and Johnson SWOT Analysis
11.2.6 Johnson and Johnson Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Business Overview and Total Revenue (2019 VS 2018)
11.3.3 GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline Hip Osteoarthritis Pain Drug Products and Services
11.3.5 GlaxoSmithKline SWOT Analysis
11.3.6 GlaxoSmithKline Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Bayer Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Bayer Hip Osteoarthritis Pain Drug Products and Services
11.4.5 Bayer SWOT Analysis
11.4.6 Bayer Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Corporation Information
11.5.2 Eli Lilly Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Eli Lilly Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Eli Lilly Hip Osteoarthritis Pain Drug Products and Services
11.5.5 Eli Lilly SWOT Analysis
11.5.6 Eli Lilly Recent Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Novartis Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Novartis Hip Osteoarthritis Pain Drug Products and Services
11.6.5 Novartis SWOT Analysis
11.6.6 Novartis Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Sanofi Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Sanofi Hip Osteoarthritis Pain Drug Products and Services
11.7.5 Sanofi SWOT Analysis
11.7.6 Sanofi Recent Developments
11.8 Horizon Pharma
11.8.1 Horizon Pharma Corporation Information
11.8.2 Horizon Pharma Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Horizon Pharma Hip Osteoarthritis Pain Drug Products and Services
11.8.5 Horizon Pharma SWOT Analysis
11.8.6 Horizon Pharma Recent Developments
11.9 Abbott
11.9.1 Abbott Corporation Information
11.9.2 Abbott Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Abbott Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Abbott Hip Osteoarthritis Pain Drug Products and Services
11.9.5 Abbott SWOT Analysis
11.9.6 Abbott Recent Developments
11.10 Mylan
11.10.1 Mylan Corporation Information
11.10.2 Mylan Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Mylan Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Mylan Hip Osteoarthritis Pain Drug Products and Services
11.10.5 Mylan SWOT Analysis
11.10.6 Mylan Recent Developments
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Corporation Information
11.11.2 Daiichi Sankyo Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Daiichi Sankyo Hip Osteoarthritis Pain Drug Products and Services
11.11.5 Daiichi Sankyo SWOT Analysis
11.11.6 Daiichi Sankyo Recent Developments
11.12 TEVA
11.12.1 TEVA Corporation Information
11.12.2 TEVA Business Overview and Total Revenue (2019 VS 2018)
11.12.3 TEVA Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 TEVA Hip Osteoarthritis Pain Drug Products and Services
11.12.5 TEVA SWOT Analysis
11.12.6 TEVA Recent Developments
11.13 Almatica Pharma
11.13.1 Almatica Pharma Corporation Information
11.13.2 Almatica Pharma Business Overview and Total Revenue (2019 VS 2018)
11.13.3 Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 Almatica Pharma Hip Osteoarthritis Pain Drug Products and Services
11.13.5 Almatica Pharma SWOT Analysis
11.13.6 Almatica Pharma Recent Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Corporation Information
11.14.2 Astellas Pharma Business Overview and Total Revenue (2019 VS 2018)
11.14.3 Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.14.4 Astellas Pharma Hip Osteoarthritis Pain Drug Products and Services
11.14.5 Astellas Pharma SWOT Analysis
11.14.6 Astellas Pharma Recent Developments
11.15 Tide Pharmaceutical
11.15.1 Tide Pharmaceutical Corporation Information
11.15.2 Tide Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.15.3 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.15.4 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Products and Services
11.15.5 Tide Pharmaceutical SWOT Analysis
11.15.6 Tide Pharmaceutical Recent Developments
11.16 Iroko Pharmaceuticals
11.16.1 Iroko Pharmaceuticals Corporation Information
11.16.2 Iroko Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.16.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.16.4 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Products and Services
11.16.5 Iroko Pharmaceuticals SWOT Analysis
11.16.6 Iroko Pharmaceuticals Recent Developments
11.17 Hengrui Pharmaceutical
11.17.1 Hengrui Pharmaceutical Corporation Information
11.17.2 Hengrui Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.17.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.17.4 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Products and Services
11.17.5 Hengrui Pharmaceutical SWOT Analysis
11.17.6 Hengrui Pharmaceutical Recent Developments
11.18 Abiogen Pharma
11.18.1 Abiogen Pharma Corporation Information
11.18.2 Abiogen Pharma Business Overview and Total Revenue (2019 VS 2018)
11.18.3 Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.18.4 Abiogen Pharma Hip Osteoarthritis Pain Drug Products and Services
11.18.5 Abiogen Pharma SWOT Analysis
11.18.6 Abiogen Pharma Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Hip Osteoarthritis Pain Drug Sales Channels
12.2.2 Hip Osteoarthritis Pain Drug Distributors
12.3 Hip Osteoarthritis Pain Drug Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.1.1 Global Hip Osteoarthritis Pain Drug Sales Forecast by Regions (2021-2026)
13.1.2 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.2.2 North America Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.2.3 North America Hip Osteoarthritis Pain Drug Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.3.2 Europe Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.3.3 Europe Hip Osteoarthritis Pain Drug Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.4.2 Asia Pacific Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Hip Osteoarthritis Pain Drug Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.5.2 Latin America Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.5.3 Latin America Hip Osteoarthritis Pain Drug Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Hip Osteoarthritis Pain Drug Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Pfizer、Johnson and Johnson、GlaxoSmithKline、Bayer、Eli Lilly、Novartis、Sanofi、Horizon Pharma、Abbott、Mylan、Daiichi Sankyo、TEVA、Almatica Pharma、Astellas Pharma、Tide Pharmaceutical、Iroko Pharmaceuticals、Hengrui Pharmaceutical、Abiogen Pharma

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 股関節変形性関節症鎮痛剤の世界市場2020-2026:経口、注射、外用(Global Hip Osteoarthritis Pain Drug Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。